BioMarin Pharma (BMRN) Tops Q2 EPS by 8c, Affirms FY Revenue Guidance, Lowers R&D Expense Guidance

BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of ($0.09), $0.08 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $372.8 billion versus the consensus estimate of $3.62 billion.

GUIDANCE:

BioMarin Pharma sees FY2018 revenue of $1.47-1.53 billion.

BioMarin Pharma sees FY2018 R&D expense of of $645-685 million, prior was for $680-710 million

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.

You May Also Be Interested In

• BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $97 at BMO Capital
• Forgent Power Solutions, Inc. (FPS) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY27 Guidance
• Vera Bradley (VRA) Tops Q2 EPS by 10c ; Offers Guidance